HomeAI · summaries
Storia in 14 fonti
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
- ·
statnews.com
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
- ·
cnbc.com
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
- ·
endpoints.news
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the…
- ·
qz.com
Eli Lilly retatrutide Phase 3 obesity trial results 2026
The triple-hormone injection outpaced existing weight loss drugs and approached bariatric surgery outcomes in an 80-week study
- ·
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness seen with bariatric surgery
- ·
thehindubusinessline.com
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.
- ·
eu.usatoday.com
New weight-loss shot more powerful than old GLP-1s, Eli Lilly says
Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.
- ·
zerohedge.com
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
"We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine."
- ·
independent.co.uk
Super Ozempic? New weight-loss drug sees even better results in recent study
Many of the patients who tested the drug lost about 30 percent of their body weight — a loss comparable to the result of bariatric surgery
- ·
washingtonexaminer.com
New Eli Lilly weight loss drug has dramatic effects in clinical trial
A new weight loss drug from Eli Lilly made patients lose 28% of their body weight on average, levels achieved only by surgery before.
- ·
time.com
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.
- ·
economictimes.indiatimes.com
Eli Lilly’s obesity drug shows up to 30% weight loss in trial
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple…
- ·
benzinga.com
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
- ·
upi.com
Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com
Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight after two years.